Johnson & Johnson, one of the largest pharmaceutical and medical companies in the world, says she plans for about $ 400 million at additional costs related to President Donald Trump’s definitions, which seems to be changing by an hour. Inaccurately, these additional costs do not include plans yet for Trump’s tariff on pharmaceutical products, which the president has repeatedly said that he will be imposed soon.
Johnson & Johnson defeated revenue expectations, an increase of 2.4 % to 21.89 billion dollars, according to the profits reported. TuesdayWith a profit of $ 11 billion in the first quarter, up from $ 3.26 billion in the previous year. But the company told analysts at a phone conference on Tuesday that the definitions of Canada and Mexico should be planned, in addition to the tariff on steel and aluminum. The definitions will be “widely”, not only in one field of the company’s portfolio, according to CNBCWith some of the largest effects on the products that are already shipped from the United States to China, which imposed a mutual tariff.
Executive officials at Johnson & Johnson in general indicate Trump that they want a decrease in taxes to help compensate for the costs of definitions, with the emergence of financial manager Joseph and Wallc. CNBC Tuesday to say that tax cuts are great for business. When asked about the CNBC host Joe Kernin, a supporter of Donald Trump, whether the policies of the president have inspired Walk to invest more in the United States, the rates for Trump’s tax cuts for 2017.
https://www.youtube.com/watch?
Joaquin Duato said something similar to his invitation with analysts on Tuesday, according to Wall Street Journal. “If what you want is to build the manufacturing capacity in the United States, whether in medtech or in medications, the most effective answer is the customs tariff, but the tax policy.”
Trump is trying to introduce tax cuts for the year 2017 and the republican budget plan has passed Last week. But there are still some conservative Republicans who do not believe that the budget reduces enough in vital services.
Even if the United States enters the recession thanks to Trump’s policies, Johnson & Johnson says he is in a good weather in difficult times because the healthcare industry is more “stagnant resistant”, according to the magazine. After all, no one really wants to get sick. Given the mainly broken nature of the health care system in the United States, there is not much in the way of choosing the consumer. Pay or die.
Just to add more chaos to this mix, Trump said he wanted definitions of imported drugs to the United States, which is believed to bring more manufacturing functions to American beaches. There is also the argument of national security that relying on foreign supply chains makes the United States at risk, which is not quite wrong because Trump turns all traditional geopolitical friends in America into enemies.
Minister of Commerce He made a notice On Monday, the achievement of section 232 was underway to study whether drug imports pose any danger to national security. Trump has already used Article 232, a ruling from the 1962 commercial expansion law, to slap the customs tariff on wood and cars under the guise of national security. The threat of “national security”, as it was, is supposed to be the American trade deficit with other countries.
Dr. Scott Gottlieb, FDA Commissioner in Trump, explained during his first term CNBC These general drugs will actually be the most difficult damage to the definitions, and given the least -sized margins on these drugs, many companies are likely to withdraw from manufacturing these drugs, which leads to a possible deficiency.
“When it comes to public medicines, they do not have a lot of pillows. I think many of these public manufacturers will get out of these markets if the definitions are imposed on them. Then we will get a lack of drugs here,” Gutliplab said. “So the same problem that they are trying to solve, which is the issue of national security related to this 232 ruling that they are trying to use, is the problem that will be less possible to use this tool.”
https://www.youtube.com/watch?
Many drugs died by US imports already come from Ireland, where adult manufacturers have been established thanks to tax incentives. But Gottlieb, who is also sitting on Pfizer’s Board of Directors, said there are great benefits from Europe that have better protection for workers and increased energy costs. Especially when the “brands” drugs are produced with a higher margin instead of medicines.
“When you look at the brand companies that manufacture these high -marginal products in Ireland, they will be ready to return a lot of this manufacturing to the United States,” said Gutliplab. “In fact, I have seen Lilly and Novartis to issue ads in recent weeks that they are returning a large part of this manufacturing because the tax advantage of manufacturing in Ireland is not great for manufacturing to the United States and more control.”
Gottlieb pointed out that it is much easier to employ the Labor Party in the United States, without explaining that one of these reasons is that workers in other rich countries like Ireland are not working. “At the willThis means that they can be expelled at any time for any reason.
“It is easier to use work here,” Gottlieb. “The biggest input in manufacturing is the costs of employment and energy costs. Energy is cheaper here. Therefore, the increasing benefit they get from transferring to Ireland due to tax treatment is not completely matched by those other advantages, but it compensates enough to be ready to do so.”
For its part, Big Parma presses the Trump system to any of the stage in any slow pharmaceutical tariff or create exemptions for certain types of products, according to what he said New York Times. Although it is possible that some pharmaceutical companies can temporarily eat some definition costs in view of the current contracts that have already been signed, there are indications that the same companies will only retract the medical research budgets in the United States to compensate, such as David Rex, CEO of Eli Lily, BBC Earlier this month.
“We cannot breach these agreements,” Rex said. ” “Usually, it is to reduce employees, research and development (R&D) I expect research and development to come first. This is a disappointing result. “
https://gizmodo.com/app/uploads/2025/04/drug-shortages-2022.jpg
Source link